Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC
Science Advances · 17.10.2025 · 11 (42)
DOI: 10.1126/sciadv.ady7930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 17.10.2025. Verfasst von Jinyu Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Resea…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Acrylamides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Osimertinib (Osi) resistance limits its efficacy in EGFR-mutant non–small cell lung cancer (NSCLC). Here, we developed a pH-responsive cationic nanovesicle ( 124 I/Cy5.5-sO@FCLs), equipped with dual-modal positron emission tomography (PET) and fluorescence imaging capabilities, to enable dynamic monitoring of the role of ribonucleotide reductase M2 subunit (RRM2) disruption in overcoming Osi resistance and enhance targeted anticancer efficacy in NSCLC. RRM2 was identified as a critical driver of poor prognosis and Osi resistance in NSCLC. The 124 I/Cy5.5-sO@FCLs enabled real-time tracking of tumor targeting and biodistribution, and CRISPR-Cas9–mediated RRM2 disruption efficiently reversed Osi resistance and potentiated synergistic anticancer effects, which was attributed to counteracting TGF-β/Smad2/3–mediated epithelial-mesenchymal transition (EMT) and amplifying cGAS/STING-induced ferroptosis. Furthermore, the nanovesicles triggered STING-dependent immunogenic cell death (ICD), stimulating tumor infiltration of dendritic cells (DCs) and T cells; combination with anti–PD-L1 therapy augmented NSCLC regression. Collectively, 124 I/Cy5.5-sO@FCLs integrate gene editing with targeted therapies while enabling dynamic, quantitative monitoring, providing an approach for precision-targeted treatment in Osi-resistant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceu…
- Key Laboratory of Green Process and Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
- Department of Interventional Radiology, Zhongshan hospital, Shanghai Institute of Medical Imaging, Shanghai Institution of Medical Imaging, Shanghai, National Clinical Research Center of Interventional Medicine, Fudan U…
- Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Hospital, School of Medicine, Zhejiang University, Lishui 323000, China.
ORCID-Profile: Jinyu Zhu, Kaihui Cui, Yuan Yao, Yang Liu, Hua Zhu, Bufu Tang, Nan Li
Zitieren
APA
Zhu, J., Cui, K., Zhou, W., Zhou, X., Yao, Y., Zhao, C., Yang, Y., Liu, Y., Tao, J., Yang, Z., Zhu, H., Tang, B., & Li, N. (2025). Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC. Science Advances, 11(42). https://doi.org/10.1126/sciadv.ady7930
Vancouver
Zhu J, Cui K, Zhou W, Zhou X, Yao Y, Zhao C, et al. Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC. Science Advances. 2025;11(42). doi:10.1126/sciadv.ady7930
BibTeX
@article{Zhu2025,
author = {Zhu, Jinyu and Cui, Kaihui and Zhou, Wenyuan and Zhou, Xin and Yao, Yuan and Zhao, Chuanke and Yang, Yuwen and Liu, Yang and Tao, Jinping and Yang, Zhi and Zhu, Hua and Tang, Bufu and Li, Nan},
title = {Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {42},
doi = {10.1126/sciadv.ady7930}
}
EUVIMED